SANGAMO THERAPEUTICS, INC

Delisting effective

• SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001001233 SANGAMO THERAPEUTICS, INC 000-30171 501 Canal Boulevard Suite A100 Richmond CA CALIFORNIA 94804 +1 510 970-6000 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-10-06”

Bankruptcy or receivership reported

• SEC EDGAR — “Item 1.03 Bankruptcy or Receivership. The information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. (the Company ) filed a voluntary petition for relief (Case No. 26-10989) under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court and such case, the Chapter 11 Case ). The Company has continued to operate its business as a debtor-in-possession under the jurisdiction of t…”

Bankruptcy or receivership reported

• SEC EDGAR — “Item 1.03 Bankruptcy or Receivership. The information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. (the Company ) filed a voluntary petition for relief (Case No. 26-10989) under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court and such case, the Chapter 11 Case ). The Company has continued to operate its business as a debtor-in-possession under the jurisdiction of t…”

Bankruptcy or receivership reported

• SEC EDGAR — “Item 1.03 of this Current Report on Form 8-K under the heading PTC Asset Purchase Agreement is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. As previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. (the Company ) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the Bankruptcy Code ) in the United States Bankruptcy Court for the District of Delaware (the Bankruptcy Court ), thereby commencing a Chapter 11 case for the Company (the Chapter 11 Case ). The case number is 26-10989 and the Chapter 11 Case is styled a…”

Bankruptcy or receivership reported

• SEC EDGAR — “Item 1.03 Bankruptcy or Receivership. As previously disclosed, on June 23, 2026 (the Petition Date ), Sangamo Therapeutics, Inc. (the Company ) filed a voluntary petition (Case No. 26-10989) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the Court and such case, the Case ). On the Petition Date, the Company filed a motion (the Bidding Procedures Motion ) (Docket No. 13) that sought approval of, among other things, certain auction and bidding procedures (the Bidding Procedures ) in connection with a sale of all…”

Delisting notice received

• SEC EDGAR — “Item 1.03 Bankruptcy or Receivership. As previously disclosed, on June 23, 2026 (the Petition Date ), Sangamo Therapeutics, Inc. (the Company ) filed a voluntary petition (Case No. 26-10989) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the Court and such case, the Case ). On the Petition Date, the Company filed a motion (the Bidding Procedures Motion ) (Docket No. 13) that sought approval of, among other things, certain auction and bidding procedures (the Bidding Procedures ) in connection with a sale of all…”

Bankruptcy or receivership reported

• SEC EDGAR — “Item 1.03 of this Current Report on Form 8-K under the heading Stalking Horse Asset Purchase Agreements is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. On June 23, 2026 (the Petition Date ), Sangamo Therapeutics, Inc. (the Company ) filed a voluntary petition (Case No. 26-10989) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the Court and such case, the Case ). The Company will continue to operate its business as a debtor-in-possession under the jurisdiction of the Court and in accord…”

Delisting notice received

• SEC EDGAR — “Item 8.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. As previously reported, on April 30, 2025, Sangamo Therapeutics, Inc. (the Company ) received a written notice (the Notice ) from the Listing Qualifications Department (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that because the closing bid price for the Company s common stock had fallen below $1.00 per share for 30 consecutive business days, it no longer complied with the minimum bid price requirement (the Minimum Bid Price Requirement ) for continued…”